Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CYTK

Cytokinetics, Incorporated

Healthcare | Biotechnology

No licensed closing price on file for CYTK. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-6.54

Cytokinetics, Incorporated (NASDAQ: CYTK) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 13:43 UTC.

What Cytokinetics, Incorporated does

Cytokinetics is a biopharmaceutical company that discovers and develops small molecule drugs designed to modulate muscle function for treating cardiovascular and neuromuscular diseases. The company's first approved product is MYQORZO (aficamten), a cardiac myosin inhibitor that received FDA approval in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy and has also been approved in Europe and China.

Summarized from Cytokinetics, Incorporated’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-6.54

Revenue, margins & earnings

FY2021: net loss $215M on revenue $70M$70MFY2021FY2022: net loss $389M on revenue $95M$95MFY2022FY2023: net loss $526M on revenue $8M$8MFY2023FY2024: net loss $590M on revenue $18M$18MFY2024FY2025: net loss $785M on revenue $88M$88MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-20
  • 2026-10-20EVP Research & DevelopmentOption exercise3,500$27.3K
  • 2026-10-20EVP Research & DevelopmentNon-Qualified Stock Option (Right to Buy)Option exercise-3,500—
  • 2026-10-20DirectorAward352$22.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Cytokinetics, Incorporated do?

Cytokinetics is a biopharmaceutical company that discovers and develops small molecule drugs designed to modulate muscle function for treating cardiovascular and neuromuscular diseases.

When did CYTK last file with the SEC?

Cytokinetics, Incorporated's most recent SEC filing on record is a 8-K filed 2026-05-27. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 13:43 UTC. This page is also available as JSON at /api/data?ticker=CYTK and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CYTK and 5,000+ tickers.

Create a free account — keep CYTK
For your agent
GET /api/data?ticker=CYTK

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt